Search for: [Abstract = "of therapy, and RF, but not ACPA seropositivity was independently associated with a better drug survival. 2. In RA patients undergoing mandatory non\-medical switch from originator RTX to its biosimilar GP2013, no deterioration in disease activity in the 2\-year follow\-up period was observed. In RA patients starting treatment with GP2013, treatment response was satisfactory, and effect remained stable after 2 years. GP2013 drug survival was comparable to data published for RTX. 3. In PsA patients with only peripheral or peripheral with axial involvement observed in 2013\- 2020 period, improvement in treatment outcomes and increase in the proportion of patients achieving remission\/low disease activity was noted, which is most likely related to more intensified treatment with bDMARDs and access to bDMARDs with new modes of action in addition to TNFi. Women had higher PROs and disease activity indices, were less likely to be treated with bDMARDs and seemed to be less likely to achieve remission\/low disease activity than men. The proportion of PsA patients achieving remission\/low disease activity varied significantly depending on remission definition used, ranging from 10% to 70%. Such a large variability of results with significant implications in everyday clinical practice, may suggest the need to verify methods currently used for assessing remission and low disease"]
